/, Interstitial Cystitis Network Blog, News, Research, Treatments/New IC Treatments Use Liposomes To Deliver BotoxA Into The Bladder

New IC Treatments Use Liposomes To Deliver BotoxA Into The Bladder

By Jill Heidi Osborne MA

jill1114bVery interesting Botox study crossed my desk today. As you probably know, Botox A has been used for the treatment of various bladder conditions for several years now. Though it’s not approved specifically for the treatment of interstitial cystitis, it is a STEP FOUR treatment option in the AUA’s IC/BPS Treatment Guidelines. The treatment requires the injection of Botox A into the bladder wall, usually at 20 to 30 injection sites.  The downside of Botox A treatment is that it can silence the nerves which control urination thus some (but not all) patients may be required to self catheterize for weeks or months afterward until the nerves become active again.

Well, in this study “Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial”, researchers in Taiwan delivered liposomes filled BotoxA into the bladder via a simple bladder instillation and found the therapy safe and effective at reducing symptoms of overactive bladder (i.e. symptoms of frequency and intensity of urgency). Best of all, this study apparently experienced very few episodes of urinary retention that have made Botox treatment so worrying and challenging for patients.

Liposomes have been the subject of numerous IC studies by Dr. Michael Chancellor in previous years. A liposome is a small, hollow sphere made with a phospholipid. Empty liposomes have been shown to relieve symptoms of irritation in the bladder as well as provide some bladder mucosal protective effects. But, because liposomes are so easily absorbed into the bladder wall, liposomes can also be used to carry medications thus making this an exciting new drug delivery system. Dr. Eliot Lander is currently using liposomes to deliver elmiron deeper into the bladder wall with encouraging results.

Much of this research is made possible by Lipella Pharmaceuticals, a company that has worked for years to develop new treatments for IC, OAB, hemorrhagic cystitis and bladder cancer.

Additional Reading:

By |2017-01-31T10:44:58+00:00December 15th, 2014|Industry News, Interstitial Cystitis Network Blog, News, Research, Treatments|Comments Off on New IC Treatments Use Liposomes To Deliver BotoxA Into The Bladder

About the Author:

My Google Profile+ Jill Heidi Osborne is the president and founder of the Interstitial Cystitis Network, a health education company dedicated to interstitial cystitis, bladder pain syndrome and other pelvic pain disorders. As the editor and lead author of the ICN and the IC Optimist magazine, Jill is proud of the academic recognition that her website has achieved. The University of London rated the ICN as the top IC website for accuracy, credibility, readability and quality. (Int Urogynecol J - April 2013). Harvard Medical School rated both Medscape and the ICN as the top two websites dedicated to IC. (Urology - Sept 11). Jill currently serves on the Congressionally Directed Medical Research Panel (US Army) where she collaborates with researchers to evaluate new IC research studies for possible funding. Jill has conducted and/or collaborates on a variety of IC research studies on new therapeutics, pain care, sexuality, the use of medical marijuana, menopause and the cost of treatments, shining a light on issues that influence patient quality of life. An IC support group leader and national spokesperson for the past 20 years, she has represented the IC community on radio, TV shows, at medical conferences. She has written hundreds of articles on IC and its related conditions. With a Bachelors Degree in Pharmacology and a Masters in Psychology, Jill was named Presidential Management Intern (aka Fellowship) while in graduate school. (She was unable to earn her PhD due to the onset of her IC.) She spends the majority of her time providing WELLNESS COACHING for patients in need and developing new, internet based educational and support tools for IC patients, including the “Living with IC” video series currently on YouTube and the ICN Food List smartphone app! Jill was diagnosed with IC at the age of 32 but first showed symptoms at the age of 12.